Kymera Therapeutics, Inc. (NASDAQ:KYMR) Sees Significant Decrease in Short Interest

Kymera Therapeutics, Inc. (NASDAQ:KYMR) saw a significant decrease in short interest in the month of June. As of June 30th, there was short interest totalling 9,380,000 shares, a decrease of 7.5% from the June 15th total of 10,140,000 shares. Based on an average daily volume of 572,300 shares, the short-interest ratio is presently 16.4 days.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on KYMR. HC Wainwright reaffirmed a “buy” rating and issued a $46.00 target price on shares of Kymera Therapeutics in a report on Monday, June 17th. Oppenheimer restated an “outperform” rating and issued a $52.00 price objective on shares of Kymera Therapeutics in a report on Wednesday, July 10th. Finally, B. Riley lifted their price objective on shares of Kymera Therapeutics from $31.00 to $36.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 9th. Seven analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $42.09.

Insiders Place Their Bets

In other news, Director Bruce Booth sold 16,740 shares of the firm’s stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $35.45, for a total value of $593,433.00. Following the completion of the transaction, the director now owns 803,792 shares of the company’s stock, valued at $28,494,426.40. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, Director Bruce Booth sold 16,740 shares of the company’s stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $35.45, for a total transaction of $593,433.00. Following the sale, the director now owns 803,792 shares of the company’s stock, valued at $28,494,426.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jared Gollob sold 23,145 shares of Kymera Therapeutics stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $45.81, for a total value of $1,060,272.45. Following the completion of the transaction, the insider now owns 95,470 shares of the company’s stock, valued at $4,373,480.70. The disclosure for this sale can be found here. Insiders have sold 502,345 shares of company stock worth $19,279,932 over the last three months. Company insiders own 15.82% of the company’s stock.

Institutional Trading of Kymera Therapeutics

A number of large investors have recently bought and sold shares of the business. Keudell Morrison Wealth Management increased its stake in Kymera Therapeutics by 7.2% in the second quarter. Keudell Morrison Wealth Management now owns 7,105 shares of the company’s stock valued at $212,000 after purchasing an additional 480 shares during the period. SG Americas Securities LLC increased its position in Kymera Therapeutics by 175.4% in the 2nd quarter. SG Americas Securities LLC now owns 10,887 shares of the company’s stock valued at $325,000 after acquiring an additional 6,934 shares during the period. DekaBank Deutsche Girozentrale increased its position in Kymera Therapeutics by 7.1% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 23,562 shares of the company’s stock valued at $950,000 after acquiring an additional 1,562 shares during the period. Virtu Financial LLC purchased a new stake in Kymera Therapeutics during the 1st quarter valued at approximately $207,000. Finally, Artal Group S.A. lifted its position in Kymera Therapeutics by 19.6% during the 1st quarter. Artal Group S.A. now owns 3,027,135 shares of the company’s stock worth $121,691,000 after acquiring an additional 496,400 shares during the period.

Kymera Therapeutics Stock Down 3.1 %

Shares of KYMR traded down $1.49 during midday trading on Wednesday, reaching $47.00. 426,769 shares of the stock were exchanged, compared to its average volume of 685,142. Kymera Therapeutics has a twelve month low of $9.60 and a twelve month high of $48.70. The business’s 50-day moving average price is $34.27 and its 200 day moving average price is $35.18.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.04. The company had revenue of $10.30 million for the quarter, compared to analyst estimates of $14.24 million. Kymera Therapeutics had a negative return on equity of 31.92% and a negative net margin of 194.67%. The firm’s revenue was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.70) earnings per share. Analysts anticipate that Kymera Therapeutics will post -2.86 EPS for the current year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.